A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
Latest Information Update: 16 Jul 2021
At a glance
- Drugs Ridinilazole (Primary) ; Vancomycin
- Indications Clostridium difficile infections
- Focus Proof of concept; Therapeutic Use
- Acronyms CoDIFy
- Sponsors Summit Therapeutics
- 12 Jul 2021 Results presented in a Summit Therapeutics media release.
- 12 Jul 2021 According to a Summit Therapeutics media release, data from this study presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
- 12 Jul 2021 Results presented in a Summit Therapeutics Media Release.